Castle Biosciences, Inc. Form 4 Filings

CASTLE BIOSCIENCES INC (CSTL) reported that Chief Commercial Officer Juvenal W. Tobin sold 1,730 shares of common stock on August 31, 2026 in an open-market transaction at a weighted-average price of $32.81 per share, with individual trade prices ranging from $32.39 to $33.17.

The sale was made pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025, and following this transaction Tobin directly holds 65,184 shares of Castle Biosciences common stock.

CASTLE BIOSCIENCES INC (CSTL) CEO and director Derek J. Maetzold reported an option exercise and related share sales. He exercised a stock option for 12,428 shares of Common Stock at an exercise price of $2.39 per share, from a fully vested option expiring May 9, 2028, leaving 25,329 option shares outstanding. On the same date, entities associated with him sold an aggregate of 18,560 shares of Common Stock, including direct holdings and shares held through several family and grantor retained annuity trusts, at weighted-average prices of approximately $33.14 and $33.88 per share. All transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2025.

CASTLE BIOSCIENCES INC (CSTL) reported an insider transaction by Chief Commercial Officer Juvenal Tobin W. On August 25, 2026, he sold 9,050 shares of common stock in an open-market transaction at a weighted-average price of $35.04 per share, with individual trade prices ranging from $35.00 to $35.14. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. After this transaction, he held 66,914 shares of Castle Biosciences common stock directly.

CASTLE BIOSCIENCES INC (CSTL) reported that Chief Operating Officer Kristen M. Oelschlager had associated entities sell a total of 24,602 shares of common stock on August 24–25, 2026. The shares were sold indirectly through The Fritz Shorter Trust at weighted-average prices between approximately $33.50 and $34.75. Oelschlager also reports a direct holding of 13,288 shares of common stock after these transactions.

CASTLE BIOSCIENCES INC (CSTL) reported that Chief Commercial Officer Juvenal Tobin W sold 1,730 shares of common stock on August 17, 2026 in an open-market or private transaction at a weighted-average price of $29.59 per share, under a Rule 10b5-1 trading plan adopted on December 10, 2025. The trades occurred in multiple lots between $29.21 and $30.01 per share, and Tobin now directly holds 75,964 shares of CSTL common stock.

CASTLE BIOSCIENCES INC (CSTL) reported that its Chief Financial Officer, Frank Stokes, sold common stock in an open-market transaction. On 2026-08-14, he sold 24,908 shares at a weighted-average price of $29.77 per share, executed in multiple trades between $29.71 and $29.97. Following this sale, he directly holds 35,177 shares of Castle Biosciences common stock.

CASTLE BIOSCIENCES INC (CSTL) CEO Derek J. Maetzold reported an option exercise and related share sales. He exercised a stock option for 1,100 shares of common stock at $2.39 per share, receiving 1,100 shares that were then sold at $30.02 per share. Additional sales totaling 7,232 shares of common stock were made by several trusts for which he or his spouse serves as trustee or beneficiary, at the same weighted-average price. After these transactions, he holds 37,757 shares directly, and various family and grantor retained annuity trusts hold between 11,534 and 40,935 shares each. All trades were made under a Rule 10b5-1 plan adopted on December 3, 2025, and the option shares exercised were fully vested.

Castle Biosciences Inc Chief Commercial Officer Juvenal Tobin W reported selling 1,301 shares of common stock on 2025-11-24 at $38.39 per share in an open-market or private transaction. Following the sale, he directly holds 77,694 shares. The trade was executed under a Rule 10b5-1 plan adopted on September 11, 2024.

Castle Biosciences (CSTL) president and CEO Derek J. Maetzold reported option exercises and related share sales on August 4–5, 2026. He exercised options covering 22,902 common shares at $2.39 per share, then he and related family trusts sold a combined 39,016 shares at weighted-average prices around $30.68–$31.34 per share. These transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2025.

Castle Biosciences chief operating officer Kristen M. Oelschlager reported selling a total of 8,586 shares of common stock on August 3, 2026, in three open-market transactions at weighted-average prices of $29.12, $30.00 and $30.62 per share, each executed across multiple trades within disclosed price ranges. These sales were made pursuant to a Rule 10b5-1 trading plan adopted on March 17, 2026, indicating they were pre-scheduled. Oelschlager also has indirect ownership of 97,251 shares held by The Fritz Shorter Trust, where she and her spouse serve as trustees and beneficiaries.

Castle Biosciences Inc Chief Commercial Officer Juvenal Tobin reported open‑market or private sales totaling 19,040 shares of common stock in four transactions on July 31 and August 3, 2026. The shares were sold at weighted‑average prices ranging from $28.2500 to $30.2640 per share under a Rule 10b5‑1 trading plan adopted on December 10, 2025.

CASTLE BIOSCIENCES INC president and CEO Derek J. Maetzold exercised stock options and sold common shares under a Rule 10b5-1 trading plan adopted on December 3, 2025. On July 31 and August 3, 2026 he exercised options covering 17,144 shares at $2.39 per share and sold an aggregate 28,646 shares at weighted-average prices of $30.152 and $30.353, respectively, including sales by The Maetzold Descendants 2020 Trust and the Derek Maetzold 2020 Irrevocable Trust. The options exercised were fully vested, and he continues to report indirect holdings through several family trusts.

Castle Biosciences CEO Derek J. Maetzold exercised stock options for 6,214 shares of common stock at $2.39 per share and reported related sales totaling 9,836 common shares on July 27, 2026. Sales from direct holdings and several family trusts occurred at weighted-average prices of $24.13 and $25.06 per share, pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2025. Following the option exercise, Maetzold held 78,903 options, and indirect holdings included 18,718, 44,323 and 40,935 common shares in three Grantor Retained Annuity Trusts.

Castle Biosciences Inc. President and Chief Executive Officer Derek J. Maetzold reported open-market sales of 4,172 shares of common stock on July 14, 2026 at a weighted-average price of about $22.92 per share, executed largely through family trusts and related entities.

He also exercised stock options for 550 shares at an exercise price of $2.39 per share. The sales were carried out under a Rule 10b5-1 trading plan adopted on December 3, 2025, and many positions are reported as indirect holdings through various Maetzold family trusts and grantor retained annuity trusts.

Castle Biosciences CEO Derek Maetzold reported option exercises and share sales in Castle Biosciences Inc. common stock. On July 1, 2026, he exercised options for 6,214 shares at $2.39 per share and related entities sold a combined 9,836 shares in open-market transactions at a weighted-average price of $24.29, pursuant to a pre-arranged Rule 10b5-1 plan.

Following these transactions, one direct holding shows 21,479 shares of common stock, and various family and grantor retained annuity trusts associated with Maetzold continue to hold additional indirect positions.

Castle Biosciences Chief Operating Officer Kristen M. Oelschlager reported open-market sales of a total of 8,586 shares of Common Stock on July 1, 2026, executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 17, 2026.

The sales were completed in two weighted-average price transactions: 8,186 shares at $24.40 per share and 400 shares at $24.78 per share, across multiple trades within disclosed price ranges. Following these transactions, she holds 21,874 shares directly and 97,251 shares indirectly through the Fritz Shorter Trust, where she and her spouse serve as trustees and beneficiaries.

CASTLE BIOSCIENCES INC Chief Operating Officer Kristen M. Oelschlager reported an open-market sale of 8,587 shares of common stock at a weighted-average price of $20.71 per share on June 16, 2026. The sale was executed as a planned transaction under a Rule 10b5-1 trading plan adopted on March 17, 2026.

Following this sale, she holds 30,460 shares of common stock directly and 97,251 shares indirectly through The Fritz Shorter Trust, where she and her spouse serve as trustees and beneficiaries.

CASTLE BIOSCIENCES INC director and CEO Derek J. Maetzold reported a mix of option exercises and pre-planned share sales involving his direct and trust-related holdings. He exercised stock options to acquire 550 shares of common stock at $2.39 per share, increasing his direct holdings before selling shares.

Entities associated with him, including several 2018 and 2020 family trusts, sold a combined 4,172 shares of common stock in open-market transactions at a weighted-average price of $20.66 per share. These sales were carried out under a Rule 10b5-1 trading plan adopted on December 3, 2025, indicating the trades were pre-scheduled. Following the transactions, Maetzold holds 21,479 shares directly and various additional indirect positions through multiple grantor retained annuity and remainder trusts.

Castle Biosciences CEO Derek J. Maetzold reported a mix of option exercises and share sales in Castle Biosciences Inc. common stock. He exercised stock options to acquire 6,214 shares at a price of $2.3900 per share and sold 9,836 shares in open-market transactions at a weighted-average price of $20.8570 per share.

Part of the sales came from entities such as The Maetzold Descendants 2020 Trust, the Derek Maetzold 2020 Irrevocable Trust and several 2018 remainder trusts, while a portion was from his direct holdings, which totaled 21,479 shares after these transactions. All sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025.

Olson Tiffany reported acquisition or exercise transactions in this Form 4 filing.

Castle Biosciences director Tiffany Olson received a grant of 11,766 Restricted Stock Units as equity compensation. Each RSU represents the right to receive one share of Castle Biosciences common stock at no purchase price.

The RSUs vest in full on the earlier of the one-year anniversary of May 28, 2027, or the day immediately before the company’s next Annual Meeting of Stockholders following the grant date. After this award, Olson holds 11,766 RSUs directly, and the filing shows no additional option or derivative positions.

Goldberg Ellen reported acquisition or exercise transactions in this Form 4 filing.

CASTLE BIOSCIENCES INC director Ellen Goldberg received a grant of 11,766 Restricted Stock Units (RSUs). Each RSU represents one share of the company’s common stock, so this award covers 11,766 shares. Following the grant, she holds 11,766 RSUs directly.

The RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders following the grant date. This is a compensation-related equity award, not an open‑market share purchase or sale.

Harrison Miles reported acquisition or exercise transactions in this Form 4 filing.

CASTLE BIOSCIENCES INC director Miles Harrison received a grant of Restricted Stock Units. On May 28, 2026, he was awarded 11,766 RSUs, each representing the right to receive one share of the company’s common stock. These RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders following the grant date. Following this award, his reported derivative holdings from this grant total 11,766 RSUs held directly.

Cotton Rodney reported acquisition or exercise transactions in this Form 4 filing.

Castle Biosciences director Rodney Cotton received a grant of 11,766 Restricted Stock Units. Each RSU represents the right to receive one share of Castle Biosciences common stock. The RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next annual meeting of stockholders following the grant date.

Caple Kim reported acquisition or exercise transactions in this Form 4 filing.

Castle Biosciences director Kim Caple received a grant of 11,766 Restricted Stock Units (RSUs) linked to the company’s common stock. Each RSU represents one share of common stock, for a total underlying amount of 11,766 shares. The RSUs vest in full on the earlier of the one-year anniversary of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders following the grant date. After this grant, Caple’s reported derivative holdings from this award total 11,766 RSUs.

BRADBURY DANIEL reported acquisition or exercise transactions in this Form 4 filing.

CASTLE BIOSCIENCES INC director Daniel Bradbury received a grant of 11,766 Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of Castle Biosciences common stock. The RSUs vest in full on the earlier of May 28, 2027, or the day immediately before the next Annual Meeting of Stockholders after the grant date. Following this award, Bradbury is reported as holding 11,766 RSUs directly.

Cole G Bradley reported acquisition or exercise transactions in this Form 4 filing.

Castle Biosciences director Cole G. Bradley received a grant of 11,766 Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of the company’s common stock, giving him 11,766 shares underlying this award after the transaction.

The RSUs vest in full on the earlier of the one-year anniversary of May 28, 2027 or the day immediately before the next Annual Meeting of Stockholders following the grant date. This is a compensation-related equity award rather than an open-market stock purchase or sale.

Castle Biosciences Inc. director Cole G. Bradley reported a compensation-related stock transaction. Bradley exercised previously granted Restricted Stock Units (RSUs), receiving 13,667 shares of Common Stock at a stated price of $0.00 per share. Following this exercise, Bradley directly holds 32,976 shares of Common Stock. Each RSU represents the right to receive one share of Common Stock, with vesting tied to the earlier of a one-year anniversary of the grant date or the day before the next Annual Meeting of Stockholders.

Castle Biosciences director Daniel Bradbury reported routine equity compensation activity. He exercised 13,667 Restricted Stock Units, receiving the same number of shares of Common Stock at a stated price of $0.00 per share.

Following the transactions, he now holds 22,340 shares of Common Stock directly and 13,291 shares indirectly through the Bradbury Family Trust, where he and Annette Bradbury serve as trustees and beneficiaries.

Castle Biosciences director Miles Harrison exercised Restricted Stock Units into common stock. On May 22, 2026, 13,667 RSUs converted into 13,667 shares of Common Stock at no cash cost, leaving him with 35,631 common shares held directly after the transaction.

CASTLE BIOSCIENCES director Tiffany Olson exercised previously granted equity awards rather than trading shares on the market. On May 22, 2026, she converted 13,667 Restricted Stock Units (RSUs) into the same number of Common Stock shares at a price of $0.00 per share, reflecting compensation rather than a cash investment.

Following this RSU settlement, Olson directly holds 39,573 shares of Castle Biosciences Common Stock. The filing shows no open-market purchases or sales and no shares withheld for taxes, indicating a straightforward vesting and settlement of RSUs, each of which represents the right to receive one share of Common Stock.

Castle Biosciences director Ellen Goldberg exercised restricted stock units into common shares. On May 22, 2026, she converted 13,667 Restricted Stock Units into 13,667 shares of Common Stock at a stated price of $0.00 per share. Following this equity award conversion, she directly holds 40,921 shares of Castle Biosciences common stock. The filing shows no open-market purchases or sales, indicating a routine compensation-related share issuance rather than a discretionary trade.

Castle Biosciences director Kim Caple exercised equity awards into common stock. On May 22, 2026, Caple converted 13,667 Restricted Stock Units into 13,667 shares of Common Stock at a price of $0.00 per share, classified as a derivative exercise rather than a market purchase.

Following this transaction, Caple directly holds 36,121 shares of Common Stock. The filing shows no open-market sales or gifts, indicating a routine compensation-related equity settlement rather than a discretionary trade. Each RSU represented the right to receive one share of Common Stock.

CASTLE BIOSCIENCES INC director Rodney Cotton acquired shares through an equity award conversion. On May 22, 2026, he exercised Restricted Stock Units into 13,667 shares of Common Stock at a stated price of $0.00 per share.

Following this transaction, Cotton directly owned 32,998 shares of Common Stock. A corresponding derivative entry shows the 13,667 Restricted Stock Units converted into the same number of Common shares, leaving no RSUs from this grant outstanding.

CASTLE BIOSCIENCES INC Chief Commercial Officer Juvenal W. Tobin exercised stock options and increased his direct common share holdings. On 2026-05-21, he exercised options for 11,210 shares of common stock at an exercise price of $3.38 per share. Following this transaction, he directly holds 98,035 shares of common stock. The exercised option, which was fully vested, now has no remaining balance.

CASTLE BIOSCIENCES INC President and CEO Derek J. Maetzold reported a series of insider trades in May 2026 involving company common stock. Across several family trusts and a personal account, entities associated with him sold a net 4,172 shares in open-market transactions at prices around $20 per share.

On the same dates, he exercised stock options to acquire 550 shares at an exercise price of $2.39 per share, increasing his direct common stock holdings. Following these transactions, one direct holding account shows 21,479 shares, while certain family trusts continue to hold tens of thousands of shares. The filing notes that these sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025, indicating the trades were scheduled in advance rather than timed discretionarily.

Castle Biosciences CEO Derek J. Maetzold reported a mix of stock option exercises and share sales in Castle Biosciences Inc. common stock. On May 7, 2026, he exercised options to acquire 6,214 shares at an exercise price of $2.39 per share, converting a derivative award into common stock.

The filing also shows open-market sales totaling 9,836 shares at weighted-average prices around $22.08–$22.585 per share. These sales occurred both in his direct account and through several family and estate-planning trusts, including the Maetzold 2018 remainder trusts and 2020 trusts for descendants.

Following these transactions, Maetzold directly holds 22,385 Castle Biosciences shares, while additional shares are held indirectly through multiple trusts where he or his spouse serves as trustee. A footnote states that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025, indicating the trades were scheduled in advance.

Entities associated with Castle Biosciences CEO Derek Maetzold reported open-market sales totaling 4,172 shares of Common Stock on April 21 at a weighted-average price of $25.098 per share. These transactions were made pursuant to a Rule 10b5-1 plan adopted on December 3, 2025.

The filing also shows Maetzold exercised stock options to acquire 550 shares at $2.39 per share and sold a matching 550 shares, leaving 21,479 shares held directly, plus additional indirect holdings in several family and grantor retained annuity trusts.

CASTLE BIOSCIENCES INC President & CEO Derek J. Maetzold reported an exercise-and-sell transaction in company stock. On April 6, 2026, he exercised stock options to acquire 6,214 shares of common stock at an exercise price of $2.39 per share, converting previously granted options into shares.

On the same date, Maetzold sold 6,214 directly held shares of common stock at a weighted-average price of about $25.03 per share, along with additional open-market sales through several family and estate-planning trusts totaling 9,836 shares sold overall. According to the filing, these sales were made under a Rule 10b5-1 trading plan adopted on December 3, 2025, indicating they were pre-scheduled rather than opportunistic trades.

After these transactions, Maetzold continues to hold 21,479 shares directly and maintains substantial indirect ownership through multiple trusts, including 48,852 shares in The Maetzold Descendants 2020 Trust and 85,959 shares in DJM Grantor Retained Annuity Trust No. 5, among other vehicles.

Castle Biosciences (CSTL) President and CEO Derek J. Maetzold reported exercising stock options and selling shares in a pre-planned transaction. He exercised options for 550 shares of common stock at $2.39 per share, then sold a total of 4,172 common shares at a weighted-average price of $25.551 per share under a Rule 10b5-1 trading plan.

After these transactions, Maetzold holds 21,479 common shares directly and 13,732 options, with additional indirect holdings through several family trusts, including 50,209 shares in The Maetzold Descendants 2020 Trust and 42,673 shares in the Derek Maetzold 2020 Irrevocable Trust.

Castle Biosciences director Rodney Cotton exercised restricted stock units to receive common shares. On March 26, 2026, he exercised 5,329 Restricted Stock Units (RSUs), each representing one share of common stock, at an exercise price of $0.00 per share.

Following the transaction, his direct holdings of Castle Biosciences common stock increased to 19,331 shares. The RSUs relate to a prior grant of 15,988 RSUs awarded on March 26, 2024, which vest in three equal annual installments beginning March 26, 2025. This filing reflects a routine compensation-related equity vesting and exercise event, not an open‑market purchase or sale.

Castle Biosciences CEO Derek J. Maetzold reported open-market sales of 19,300 shares of Common Stock of CASTLE BIOSCIENCES INC. He sold 18,650 shares at a weighted-average price of $25.93 on March 17, 2026 and 650 shares at $25.39 on March 18, 2026, leaving 21,479 shares held directly.

The filing notes these transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. Maetzold also reports indirect ownership of additional Common Stock through multiple family and grantor retained annuity trusts, including 51,566 shares held by The Maetzold Descendants 2020 Trust and other trusts where he serves as trustee or beneficiary.

Castle Biosciences Inc. President and CEO Derek J. Maetzold reported open-market sales of a total of 30,779 shares of common stock on March 13 and 16, 2026, at weighted-average prices of $25.447, $25.964 and $26.680 per share. These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 3, 2025. Following the sales, he holds 40,779 shares directly and also has indirect holdings through several family and grantor retained annuity trusts.

CASTLE BIOSCIENCES INC Chief Commercial Officer Juvenal Tobin reported an open-market sale of 20,863 shares of common stock. The shares were sold at a weighted-average price of $25.24 per share, with individual trade prices ranging from $24.90 to $25.70. After this transaction, Tobin directly holds 86,825 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the timing was set in advance rather than decided opportunistically.

Castle Biosciences President and CEO Derek J. Maetzold reported a pre-planned combination of option exercise and share sales. On March 11, 2026, he exercised a fully vested stock option for 6,226 shares of common stock at $2.39 per share and received the underlying shares.

That same day, Maetzold and several family-related trusts sold multiple blocks of common stock in open-market transactions at a weighted-average price of about $26.11. On March 12, 2026, he sold an additional 23,179 shares at an average price of $25.279 per share. All sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2025. After these trades, he holds 71,558 shares directly, plus additional indirect holdings through various trusts.

Castle Biosciences Chief Financial Officer Frank Stokes sold 6,001 shares of common stock on March 5, 2026 in an open-market transaction at a weighted-average price of $27.98 per share. The sale was made under a prearranged Rule 10b5-1 trading plan adopted on November 13, 2025.

The transaction was executed in multiple trades at prices ranging from $27.51 to $28.41 per share, with the reported price reflecting the weighted average. After this planned sale, Stokes continues to directly own 60,085 shares of Castle Biosciences common stock.

Castle Biosciences director Cole G Bradley reported option exercises and stock sales. On March 5, 2026, Bradley exercised stock options for 4,748 shares and received an equal number of common shares. He then sold a total of 7,403 common shares in open-market transactions and held 19,309 shares directly afterward.

Castle Biosciences Chief Commercial Officer Juvenal Tobin W reported several equity compensation transactions in early March 2026. On March 3, he received a grant of 48,367 Restricted Stock Units (RSUs), each representing one share of common stock, which will vest in four equal annual installments beginning March 3, 2027.

On March 4, previously granted RSUs were exercised into common stock, and 10,399 shares and 3,716 shares of common stock were withheld to cover tax obligations in connection with vested performance or restricted stock units. After these transactions, his directly held common stock and RSU positions increased overall.

Castle Biosciences Chief Operating Officer Kristen M. Oelschlager reported several equity compensation transactions involving restricted stock units (RSUs) and common stock. On March 3, 2026, she received a grant of 48,367 RSUs, which vest in four equal annual installments beginning on March 3, 2027.

On March 4, 2026, she exercised or converted RSUs covering 13,811 and 11,960 RSUs at a price of $0.00 per unit, resulting in 25,771 shares of common stock acquired through derivative exercises. The filing also reports dispositions of 6,792 and 2,427 shares of common stock at $28.17 and $27.57 per share, respectively, to satisfy tax withholding obligations in connection with vested performance stock units.

Following these transactions, she holds common stock directly and also has an indirect holding of 97,251 shares of common stock through The Fritz Shorter Trust, of which she and her spouse are trustees and beneficiaries. Each RSU represents the right to receive one share of Castle Biosciences common stock.

Castle Biosciences president and CEO Derek J. Maetzold reported several equity compensation transactions in company stock. On March 3, 2026, he received a grant of 102,597 Restricted Stock Units (RSUs), which, according to a footnote, vest in four equal annual installments beginning on March 3, 2027.

On March 4, 2026, RSUs previously granted were converted into a total of 59,097 shares of common stock through derivative exercises. On March 3 and March 4, 2026, a combined 36,974 shares of common stock were disposed of at prices of $27.57 and $28.17 per share to satisfy tax withholding obligations.

The filing also lists indirect holdings of common stock in multiple trusts, including The Maetzold Descendants 2020 Trust and several Maetzold remainder and grantor retained annuity trusts, where Maetzold or his spouse serves as trustee and certain family members are beneficiaries.